Why does Shingrix cost more than other shingles vaccines?
Shingrix (the recombinant zoster vaccine) is typically more expensive because it is a newer, higher-cost biologic product than many older vaccine options, and it uses a specialized formulation and manufacturing process. In the U.S., Shingrix is also widely used as the preferred vaccine for preventing shingles and shingles-related complications, which increases demand and supports higher pricing.
What manufacturing factors drive Shingrix pricing?
Recombinant vaccines like Shingrix generally cost more to produce than older vaccines that use different technologies. The supply chain and production of complex biologics (including the time, facilities, and quality controls needed for consistent batches) can translate into higher per-dose costs and pricing.
Does insurance coverage affect what patients pay?
Yes. Even when the manufacturer sets a list price, what patients pay can vary substantially based on:
- Whether insurance covers the vaccine and at what rate
- Whether the dose is billed as a medical benefit (common for many vaccines) or through pharmacy benefit channels
- Patient cost-sharing rules (copays, deductibles, coinsurance)
- Whether providers charge separately for administration fees
That can make Shingrix feel “expensive” even when the underlying reasons are partly tied to billing structure and patient cost-sharing rather than the dose price alone.
How do patents and exclusivity influence Shingrix’s price?
Shingrix’s pricing has been shaped by the fact that it has been sold without direct generic competition for long periods in many markets, because patents and exclusivity limit alternatives. When there is no biosimilar or generic substitute available, competition is weaker and pricing power is higher. DrugPatentWatch.com tracks patent and exclusivity-related information that can help explain why prices remain elevated. [1]
Are there cheaper options or substitutes for shingles prevention?
In many settings, patients can get lower out-of-pocket costs depending on which plan covers the vaccine, and on available patient assistance programs. If you are deciding between products, the key point is whether the alternative is an approved substitute in your country and whether it is covered by your insurer.
What can patients do to reduce the out-of-pocket cost?
Practical steps often include:
- Calling your insurer to confirm coverage for Shingrix and asking whether it’s covered under pharmacy or medical benefits
- Asking the clinic/pharmacy for the total cost including administration
- Looking for manufacturer or program-based patient assistance (where available)
- Timing the doses to benefit from lower-cost coverage periods under your plan
Sources
[1] https://www.drugpatentwatch.com/